BWX Technologies, Inc.

What they do

BWXT operates two reportable segments: Government Operations and Commercial Operations. Government Operations engineers and manufactures precision naval nuclear components, reactors and nuclear fuel for the DOE/NNSA Naval Nuclear Propulsion Program and manages high-consequence operations at U.S. nuclear weapons sites and laboratories. Commercial Operations supplies precision components, nuclear fuel and services for the commercial nuclear power industry, primarily in Canada, and produces medical radioisotopes and radiopharmaceuticals.

Revenue drivers

• Government Operations — Revenue is largely a function of U.S. national security spending, primarily naval nuclear components, reactors and fuel for the Naval Nuclear Propulsion Program. In 2Q26 the segment generated $601.3M of the $901.6M consolidated revenue, or about 67%.
• Commercial Operations — Revenue depends on demand for commercial nuclear power, including maintenance and refueling outages, nuclear fuel and fuel handling equipment mainly in Canada, plus medical isotopes. 2Q26 revenue was $302.5M, up 72% year over year, about 34% of consolidated revenue.
• Medical radioisotopes and radiopharmaceuticals — A smaller product line within Commercial Operations for diagnostic imaging and radiotherapeutic treatments. The company announced the sale of the medical business in the 2Q26 earnings release and described it as the platform from which it had planned to launch Molybdenum-99 and future products.
• Special materials and site services — Within Government Operations, BWXT downblends Cold War-era high-enriched uranium, manufactures high-purity depleted uranium, and manages and operates DOE, NASA and other federal nuclear sites, laboratories and manufacturing complexes, including through joint ventures.

Recent performance

Second quarter 2026 revenue was $901.6M, up 18% from $764.0M a year earlier, with Government Operations up 2% to $601.3M and Commercial Operations up 72% to $302.5M. Consolidated operating income was $114.1M and net income was $89.1M; diluted GAAP EPS was $0.97 versus $0.85 in 2Q25, and non-GAAP EPS was $1.07. Adjusted EBITDA rose 7% to $155.5M, as Commercial Operations adjusted EBITDA more than doubled to $36.1M while Government Operations adjusted EBITDA declined 5% to $126.5M. Free cash flow was $115.0M, down from $126.3M, as capital expenditures rose 27% to $41.4M. For full year 2025, revenue was $3.20B and net income was $328.9M.

Strategy

Management is focused on nuclear national defense and commercial nuclear power, and said the announced sale of the medical business enables increased focus and resources in those core lines. BWXT closed the acquisition of Precision Components Group, LLC on July 1, 2026, establishing a U.S. footprint for commercial nuclear component manufacturing. The company is making capital expenditures and investments in personnel to meet current demand, including capacity and modernization across its manufacturing footprint. It expects to fund growth investments and acquisitions with cash from operations or by raising additional capital through debt, equity or a combination. The 10-K notes the U.S. Navy's March 2024 30-year shipbuilding plan showed all three procurement profiles indicating growth in total ships and sustained or increased nuclear-powered submarine and aircraft carrier procurement.

Risks

• U.S. Government contract concentration — U.S. Government contracts, directly or as a sub-tier contractor, comprised approximately 68% of total consolidated revenues for the year ended December 31, 2025, and are subject to termination or modification at the government's convenience.
• Annual appropriations and budget uncertainty — Many large multi-year contracts are subject to annual funding determinations and Congressional appropriations, so reductions in DOE funding or continuing resolutions could delay or curtail programs important to Government Operations.
• Commercial nuclear cyclicality — Commercial Operations revenue depends on the timing of maintenance and refueling outages, the cyclical nature of capital expenditures and plant life extension projects, and demand for nuclear fuel and fuel handling equipment primarily in Canada, which can cause variability in results.
• Contract cost estimation risk — Revenue is recognized over time using costs incurred as a percentage of total estimated project costs, so periodic revisions to contract price or cost estimates affect income in the period revised, and projected losses are recognized in full when determined.

Outlook

For 2026, management raised guidance to adjusted EBITDA of $662 million to $672 million, non-GAAP EPS of $4.70 to $4.80, and free cash flow of $345 million to $360 million, citing strong first-half performance, contribution from the completed PCG acquisition and confidence in execution. The company expects to recognize approximately 40% of revenue associated with its backlog by the end of 2026, with the remainder recognized thereafter. Management stated demand for new nuclear solutions is deep and broad, complementing predictable revenue streams in Government and Commercial segments. BWXT cautions that reductions in federal government spending could adversely affect future operating results and cash flows of Government Operations.